Advanced glycation end products induce oxidative stress and mitochondrial dysfunction in SH-SY5Y cells

Area of Science:

• Neuroscience
• Cell Biology
• Biochemistry

Background:

• Advanced glycation end products (AGEs) are implicated in diabetic complications and neurodegenerative diseases.
• Mitochondrial dysfunction is a key feature in diseases like Alzheimer's disease.
• The role of AGEs in directly inducing neuronal mitochondrial dysfunction requires elucidation.

Purpose of the Study:

• To investigate the direct impact of AGEs on mitochondrial structure and function in SH-SY5Y neuroblastoma cells.
• To explore the molecular mechanisms by which AGEs induce mitochondrial dysfunction.
• To determine the involvement of the receptor for advanced glycation end products (RAGE) pathway.

Main Methods:

• SH-SY5Y cells were exposed to AGE-bovine serum albumin (BSA).
• Mitochondrial function was assessed by measuring reactive oxygen species (ROS) and mitochondrial membrane potential (ΔΨm).
• Cytochrome c (Cyt c) release and mitochondrial morphology were analyzed using Western blotting and transmission electron microscopy, respectively.
• The role of RAGE was investigated using a neutralizing anti-RAGE antibody.

Main Results:

• AGE-BSA treatment significantly increased ROS levels and decreased mitochondrial membrane potential (ΔΨm) in SH-SY5Y cells.
• AGE-BSA induced the release of cytochrome c (Cyt c) from mitochondria and caused mitochondrial swelling and vacuolization.
• Pretreatment with anti-RAGE antibody attenuated these AGE-BSA-induced mitochondrial changes.

Conclusions:

• Advanced glycation end products (AGEs) directly induce mitochondrial dysfunction in neuronal cells (SH-SY5Y) via the RAGE pathway.
• AGE-induced mitochondrial damage involves increased oxidative stress, loss of membrane potential, and cytochrome c release.
• AGEs represent a potential mechanistic link between diabetes mellitus and Alzheimer's disease pathogenesis.